Loading people...
Anat Nursella is a Venture Partner at OrbiMed, a global healthcare investment firm she joined in 2021. She brings over 17 years of experience in senior financial and operational roles within the biotechnology sector, supporting fundraising, licensing, and M&A transactions exceeding $1 billion in total value. Prior to her current position, Nursella served as Chief Financial Officer for multiple life sciences companies, including ImmPact Bio and Adicet Bio. Her executive tenure also includes financial leadership at cCam Biotherapeutics, which was acquired by Merck, and Keystone Heart, purchased by Venus Medtech. A Certified Public Accountant, she holds a Master of Arts in Law from Bar-Ilan University and a Bachelor of Arts in Finance and Economics from the University of Haifa. Nursella currently focuses on guiding healthcare investments and serving as a board director for biotechnology enterprises.
Anat Nursella is a highly respected Venture Partner at OrbiMed, one of the world's largest and most active healthcare-dedicated investment firms. In this pivotal role, Ms. Nursella is instrumental in shaping OrbiMed's investment strategy and identifying promising opportunities within the dynamic life sciences industry. Her work involves deep dives into emerging technologies and disruptive business models that have the potential to significantly impact patient care and global health outcomes.
Ms. Nursella's investment focus at OrbiMed spans a broad spectrum of healthcare sub-sectors. She is particularly interested in biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health solutions. Her expertise lies in evaluating companies from early-stage development through commercialization, assessing their scientific merit, market potential, and operational capabilities. She actively seeks out innovative companies that are developing novel therapies, advanced medical technologies, or transformative healthcare services designed to address unmet medical needs.
Prior to her tenure as a Venture Partner at OrbiMed, Anat Nursella built a robust career marked by significant contributions across various facets of the life sciences sector. While specific details of her early career are not publicly detailed, professionals in her position typically bring a wealth of experience from roles in research and development, corporate strategy, business development, or prior venture capital and private equity endeavors within healthcare. This background equips her with a comprehensive understanding of the scientific, clinical, regulatory, and commercial challenges inherent in bringing new healthcare innovations to market. Her strategic insights are invaluable to OrbiMed's portfolio companies, guiding them through critical growth phases.
As a key member of the OrbiMed team, Ms. Nursella contributes to the firm's impressive track record of successful investments. While individual notable investments are typically attributed to the firm's collective efforts, her role involves actively sourcing, evaluating, and supporting companies that become part of OrbiMed's diverse portfolio. Her commitment to fostering innovation and her deep industry knowledge make her a vital asset in OrbiMed's mission to invest in the future of healthcare globally.
Anat Nursella is a Venture Partner at OrbiMed, a leading global investment firm focused exclusively on the healthcare sector. She plays a key role in identifying and investing in innovative life sciences companies.
Anat Nursella invests in a wide range of healthcare and life sciences companies. Her focus areas include biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health solutions, seeking out innovations that address significant medical needs.
Anat Nursella works as a Venture Partner at OrbiMed. OrbiMed is a prominent investment firm dedicated to the healthcare industry, with offices globally.
